The Effects of ∆-9-THC and Naloxone in Humans

Yale University

Status and phase: Completed; Early Phase 1

Conditions: Healthy

Treatments: Drug: Delta-9-THC; Drug: Placebo; Drug: Naloxone

Study type: Interventional

Funder types: Other

Identifiers

NCT01591629

1108008940

Details and patient eligibility

About

The purpose of this project is to examine the effects of mu-opiate antagonism on the rewarding and reinforcing effects of delta-9-tetrahydrocannabinol (THC), the main psychoactive ingredient of cannabis.

Enrollment: 6 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• At least one exposure to Cannabis

Exclusion criteria

• Cannabis Naive

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

6 participants in 4 patient groups, including a placebo group

Placebo and Placebo

Placebo Comparator group

Treatment:

Drug: Placebo

Active Naloxone and Placebo

Experimental group

Treatment:

Drug: Naloxone

Drug: Placebo

Placebo and Active Delta-9-THC

Placebo Comparator group

Treatment:

Drug: Delta-9-THC

Drug: Placebo

Active Naloxone and Active Delta-9-THC

Experimental group

Treatment:

Drug: Naloxone

Drug: Delta-9-THC